BEREND JAN BOSCH,BERT JAN HAIJEMA,CORNELIS ALEXANDER MARIA DE HAAN,CORNELIS JOHANNES LEENHOUTS,MAARTEN LEONARDUS VAN ROOSMALEN,PETRUS JOSEPHUS MARIE ROTTIER
申请号：
BR112013024157
公开号：
BR112013024157A2
申请日:
2012.03.22
申请国别(地区):
BR
年份:
2016
代理人:
摘要：
title: immunogenic compositions in particulate form and methods for producing the same. abstract the invention relates to the field of immunology and vaccine development, in particular to the development of vaccines based on native antigen oligomers. provided is an immunogenic composition in particulate form, including oligomers of a surface exposed polypeptide of pathogenic origin or tumor origin, or antigenic part thereof, said oligomers being bound non-covalently to a particulate carrier, and a pharmaceutically acceptable diluent or excipient. also provided is a recombinant polypeptide comprising (a) an antigenic domain c-terminal, comprising at least one surface exposed polypeptide of pathogenic or tumor origin, or antigenic part thereof, the antigenic domain being fused to (b) an oligomerization domain (omd), said oligomerization domain being fused via (c) a linker domain to (d) a peptidoglycan binding domain (pbd) consisting of a single copy of a lysm domain capable of mediating the non-covalent attachment of the polypeptide to a non -viable bacterium-like particle (blp) obtained from a gram-positive bacterium. patent abstract: "immunogenic compositions in particulate form and methods for their production". The invention relates to the field of immunology and vaccine development, in particular the development of vaccines based on native antigen oligomers. An immunogenic composition in particulate form is provided, comprising oligomers of a surface-exposed polypeptide of pathogenic origin or tumor origin or antigenic part thereof, said oligomers being non-covalently linked to a particulate carrier, and a pharmaceutically diluent or excipient. acceptable. also provided is a recombinant polypeptide comprising (a) an n- or c-terminal antigenic domain, comprising at least one surface exposed polypeptide of pathogenic or tumor origin or antigenic part thereof, the antigenic domain being fused to (b) a oligomerization (omd), said oligomerization domain being fused th
